Liprolog Mix25 (Insulin Lispro)

Insulin Lispro is a rapid‑acting insulin analog used in the management of diabetes mellitus.

• Type 1 diabetes mellitus: provides mealtime glucose control and reduces hyperglycaemic episodes.
• Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycaemic levels.

• Insulin Lispro binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote translocation of glucose transporter‑4 (GLUT‑4) to the cell surface, enhancing glucose uptake in muscle and adipose tissue. It also suppresses hepatic glucose production, leading to rapid reduction of post‑prandial blood glucose concentrations.

Insulin Lispro may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypoglycaemia: symptoms of low blood glucose such as sweating, tremor, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with improved glycaemic control.
• Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects

• Severe hypoglycaemia: prolonged or unconscious episodes requiring assistance.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Lipohypertrophy or lipoatrophy: significant alteration of fat tissue that may affect insulin absorption.

When using Insulin Lispro, several precautions should be observed to ensure safe and effective therapy.

• Dose individualization: adjust the dose based on frequent blood glucose monitoring and clinical response.
• Hypoglycaemia risk: educate patients to recognize early signs and have rapid‑acting carbohydrates available.
• Renal impairment: use with caution as reduced clearance may increase hypoglycaemia risk.
• Pregnancy and lactation: consult a healthcare professional before initiating therapy.
• Concomitant medications: review all drugs for potential interactions that may affect glucose control.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Lispro can interact with other medicines, influencing its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid)

• Beta‑blockers: may blunt the adrenergic warning signs of hypoglycaemia.
• Alcohol: can potentiate insulin‑induced hypoglycaemia, especially with missed meals.

Moderate Interactions (Monitor Closely)

• Thiazolidinediones: combined use may increase fluid retention and oedema.
• ACE inhibitors or ARBs: may enhance insulin sensitivity, requiring dose adjustments.
• Loop diuretics: can affect potassium balance, potentially altering insulin action.